Pharvaris NV

Pharvaris NV’s clinical‑stage biotech focus on oral B2 receptor antagonists and its €1.44 bn market cap highlight potential breakthrough therapies amid volatile stock performance.

Pharvaris NV’s stock price plummeted after a $175 million public offering, but the company aims to use the funds to accelerate its drug development pipeline and potentially turn its financial metrics around.

Pharvaris NV, a clinical-stage biopharmaceutical company, faces financial challenges and stock volatility as it prepares to present clinical data at an upcoming conference.